- The Long-term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro (R) ) Coated Stent in Patients with Coronary Artery Disease
-
Kim W, Jeong MH, Hong YJ, Lee SH, Park WS, Kim JH, Kim IS, Choi MJ, Ahn YK, Cho JG, Park JC, Cho DL, Kim H, Kang JC
- KMID: 1109520
- Korean J Intern Med.
- 2004 Dec;19(4):220-229.
BACKGROUND: Previously, the inhibition of coronary restenosis with Abciximab (ReoPro (R) ) -coated stent in a porcine model was reported. ReoPro (R) inhibits platelet aggregation, the proliferation of vascular smooth... -
- CITED
-
- Close
- SHARE
-
- Close
- Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease
-
Lee JB, Lee KA, Lee KY
- KMID: 1108064
- Yonsei Med J.
- 2011 Sep;52(5):734-738.
- doi: 10.3349/ymj.2011.52.5.734
PURPOSE: Clopidogrel is a prodrug that requires transformation into an active metabolite by cytochrome P450 (CYP) in the liver in order to irreversibly inhibit the P2Y12 adenosine diphosphate platelet receptor.... -
- CITED
-
- Close
- SHARE
-
- Close
